Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCBX.L Regulatory News (CBX)

  • There is currently no data for CBX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Grant of Warrants and Extension of Exercise Period

6 May 2021 07:00

RNS Number : 6850X
Cellular Goods PLC
06 May 2021
 

Press Release

6 May 2021

 

Cellular Goods PLC

('Cellular Goods' or 'the Company')

Grant of Warrants and Extension of exercise period of Warrants

 

Cellular Goods, a UK-based provider of premium consumer products based on biosynthetic cannabinoids (LSE: CBX), announces that it has granted certain warrants over ordinary shares of £0.001 each in the capital of the Company (Ordinary Shares) to new members of the Cellular Goods team, and has agreed to extend the exercise period of certain previously granted warrants.

Granting of warrants

The Company is pleased to have secured the services of a Quality Assurance Manager and a Lead Project Manager, each of whom will have an important role in the Company's development and each of whom is being granted warrants over 250,000 Ordinary Shares at the average of the mid-market closing price for the five business days prior to grant, being 8.13 pence per share.

The warrants have a total exercise period of three years, with 25% vesting after, respectively, 6, 12, 18 and 24 months. Any shares acquired under the terms of the warrants must be held until 12 months from admission on 26 February 2021.

The Company is also pleased to have secured the services of a skincare business adviser, who is being granted warrants in July over 200,000 Ordinary Shares at the average of the mid-market closing price for the five business days prior to grant.

These warrants have a total exercise period of three years, vesting one year beyond an initial three-month advisory period subject to continuing beyond that date.

Extension of warrants

The Company has agreed a 12-month extension to the exercise period with holders of warrants over an aggregate of 6,500,000 new Ordinary Shares at an exercise price of £0.01 per share. The warrants are now exercisable for a period of three years from admission of the Company's shares to the Official List and to trading on the London Stock Exchange's Main Market (Admission), however the warrant holders have agreed not to exercise the warrants within 12 months of Admission.

The information communicated in this announcement is inside information for the purposes of Article 7 of Regulation 596/2014.

 

For further information, please contact:

Cellular Goods

 

Alexis Abraham

Chief Executive

Neil Thapar

Investor Relations

+44 20 7031 6871

 

 

+44 7876 455323

Tennyson Securities

 

Corporate Broker

Peter Krens

 

+44 20 7186 9030

Novum Securities

 

Corporate Broker

Colin Rowbury

Jon Belliss

 

 

+44 20 7399 9427 

Tancredi Intelligent Communication

 

Media Relations

Helen Humphrey

Edward Daly

Salamander Davoudi

cellulargoods@tancredigroup.com

 

+44 7449 226720

+44 7954 292488

+44 7957 549906

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IOEUPUQAAUPGGAA
Date   Source Headline
28th Mar 20224:35 pmRNSPrice Monitoring Extension
28th Mar 202211:00 amRNSPrice Monitoring Extension
22nd Mar 20227:00 amRNSDirectorate change
14th Mar 20224:41 pmRNSSecond Price Monitoring Extn
14th Mar 20224:36 pmRNSPrice Monitoring Extension
14th Mar 20222:05 pmRNSSecond Price Monitoring Extn
14th Mar 20222:00 pmRNSPrice Monitoring Extension
14th Mar 20227:00 amRNSLaunch of outdoor marketing campaign
8th Mar 202211:03 amRNSShare purchase by CEO
7th Mar 202211:05 amRNSSecond Price Monitoring Extn
7th Mar 202211:00 amRNSPrice Monitoring Extension
4th Mar 20224:41 pmRNSSecond Price Monitoring Extn
4th Mar 20224:36 pmRNSPrice Monitoring Extension
2nd Mar 20227:00 amRNSExercise of Warrants
1st Mar 20227:00 amRNSLaunch of Rejuvenating Cannabinoid Face Serum
23rd Feb 20224:41 pmRNSSecond Price Monitoring Extn
23rd Feb 20224:36 pmRNSPrice Monitoring Extension
23rd Feb 20222:06 pmRNSSecond Price Monitoring Extn
23rd Feb 20222:01 pmRNSPrice Monitoring Extension
21st Feb 202211:05 amRNSSecond Price Monitoring Extn
21st Feb 202211:00 amRNSPrice Monitoring Extension
21st Feb 20229:05 amRNSSecond Price Monitoring Extn
21st Feb 20229:00 amRNSPrice Monitoring Extension
21st Feb 20227:00 amRNSStrategy and trading update
2nd Feb 20227:00 amRNSWhite paper on cannabinoids and skin aging
7th Jan 20221:00 pmRNSResults of Annual General Meeting
15th Dec 20217:00 amRNSAnnual General Meeting update
8th Dec 20217:00 amRNSGrant of Options to CEO
6th Dec 20211:57 pmRNSPosting of Annual Report and Notice of AGM
6th Dec 20217:00 amRNSAppointment of new CEO
3rd Dec 20217:00 amRNSAnnual results
1st Dec 20217:00 amRNSLaunch of inaugural products & ecommerce platform
11th Nov 20217:00 amRNSAdvertising and PR agencies appointed
8th Nov 20212:05 pmRNSSecond Price Monitoring Extn
8th Nov 20212:00 pmRNSPrice Monitoring Extension
8th Nov 202111:05 amRNSSecond Price Monitoring Extn
8th Nov 202111:00 amRNSPrice Monitoring Extension
1st Nov 20217:00 amRNSGrant of Share Options and update on warrants
4th Oct 20219:06 amRNSSecond Price Monitoring Extn
4th Oct 20219:00 amRNSPrice Monitoring Extension
4th Oct 20217:00 amRNSDirector dealings & TR1 notification
16th Aug 20217:00 amRNSSupply agreement signed with Chanelle McCoy Health
2nd Aug 20217:00 amRNSShare disposal by significant shareholder
28th Jul 20212:06 pmRNSSecond Price Monitoring Extn
28th Jul 20212:00 pmRNSPrice Monitoring Extension
10th Jun 20217:00 amRNSSupply agreement signed with Willow Biosciences
25th May 20217:00 amRNSCellular Goods Interim Results
6th May 20217:00 amRNSGrant of Warrants and Extension of Exercise Period
20th Apr 20212:00 pmRNSPrice Monitoring Extension
12th Apr 20217:00 amRNSCellular Goods boosts team with five appointments

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.